Sanyou Bio closes exclusive Series C, lifting total funding to nearly RMB300m
Sanyou Bio has closed an exclusive Series C from Zero2IPO Industry Investment, bringing total funding to nearly RMB300m as it builds an AI-driven drug-discovery platform.
What happened
Sanyou Bio closed an exclusive Series C from Zero2IPO Industry Investment, taking total funding to nearly RMB300m. The company describes the capital as backing an AI-driven ecosystem for innovative drug discovery and translation. It is a single strategic investor, not a syndicate, and terms were not disclosed.
The numbers
- Round: exclusive Series C.
- Investor: Zero2IPO Industry Investment.
- Total raised: nearly RMB300m.
- Terms: not disclosed.
Why it matters
Antibody and protein discovery services in China are consolidating around platforms that pair AI design with wet-lab validation. A strategic investor can bring customers, data and licensing introductions, which matters more to a services business than a higher headline price.
The counter-argument is that an exclusive round concentrates influence in one shareholder and can narrow the company's options if it later needs a large syndicate. Without terms, it is also unclear how much of the nearly RMB300m is equity and how much is structured. The strategic logic, however, is clear: capital is moving into discovery platforms ahead of the next licensing cycle.
What to watch
- The commercial terms behind the exclusive arrangement.
- Sanyou's licensing pipeline and any pharma partnerships.
- Whether Zero2IPO introduces portfolio companies as customers.
Original source: Manila Times · 9 Nov 2026
